U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07751991) titled 'A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML' on July 30.
Brief Summary: The goal of this study is to evaluate the safety of CHM-029, an investigational oral medicine, and to evaluate its activity in treating certain types of acute myeloid leukemia (AML) in adults. The main questions the study aims to answer are:
* What is an appropriate dose of CHM-029?
* What side effects may occur with CHM-029?
* How does the body process CHM-029?
Researchers will evaluate increasing dose levels of CHM-029 to better understand its safety and how the body responds to treatment.
Participants will visit the...